Veritone, Inc. (VERI) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Category archives: Stocks
Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release
Profound Medical (PROF) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National CineMedia (NCMI) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release
National CineMedia (NCMI) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eagle Bulk Shipping (EGLE) Earnings Expected to Grow: Should You Buy?
Eagle Bulk Shipping (EGLE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Algonquin Power & Utilities (AQN) Reports Next Week: What You Should Expect
Algonquin Power & Utilities (AQN) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Titan International (TWI) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release
Titan International (TWI) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag
Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
2 Tech Stocks to Buy on Weakness
It’s been a turbulent start to the year for Tech, with the Nasdaq 100 Index (QQQ) sliding more than 18% from its highs and the Nasdaq Composite down more than…
SoFi’s (SOFI) Bullish Option Activity Reveals Opportunity
A significant SOFI reversal looks to be forthcoming after a treacherous 3 months of overdone selling, let’s trade it!
Is a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season?
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.